Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable).
Dr. Ralph Meyer Phase III Young Investigator Award
Congratulations from everyone at CCTG, The Ralph Meyer Young Investigator Award was presented to Dr Prica at the Annual Spring Meeting last week. The award hours MD, fellow, PhD within 10 years of certification / first faculty appointment or current fellow who has either spent time at CCTG Central Office, worked on Phase III projects with Disease Site Committees / Endpoint Committees / Working Groups, or who has contributed significantly to the conduct of a Phase III trial at a centre.
CCTG is proud to announce that the 2021 Founders Award was presented to Dr. Michael Crump this past weekend at the CCTG Spring Meeting. The Founder's Award is presented annually to an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This award honours an Investigator whose excellence in clinical trials research has provided techniques, information or concepts that will direct the future of the oncology research community and CCTG.
Congratulations to these trial teams and their member centres for their efforts and dedication to the success of CCTG clinical trials, these recipients were announced at the 2021 CCTG Annual Spring Meeting of Participants last week.
Congratulations to the 2021 Winners Dr. Michael Ong and Dr. Albiruni Abdul Razak announced at the CCTG Spring Meeting last week. The Elizabeth Eisenhauer Young Investigator Award is presented to any MD, fellow, or PhD, within 7 years of certification / first faculty appointment, or current fellow who has either spent time at CCTG Central Office, worked on projects with the Investigational New Drug (IND) Program or who has contributed significantly to the conduct of an IND trial at a participating centre.